Is BPC-157 Coming Back? The 2026 FDA Compounding Review, Explained

BPC-157 is one of several peptides that were restricted to FDA Category 2 in 2023, which made them ineligible for compounding under Section 503A. In 2026 an FDA advisory committee began reviewing some of these substances again. If you have seen claims that peptides are "coming back" and want to know what is actually settled versus still under review, this explains it. Nothing here is a promise of availability.

First: what are peptides?

Peptides are short chains of amino acids - the same building blocks your body uses to make proteins, hormones, and enzymes. Your body already produces thousands of them naturally. They regulate everything from how fast you heal a cut, to how well you sleep, to how your immune system fights infection.

What makes peptides exciting is how specific they are. Unlike broad-spectrum drugs that affect your whole body, individual peptides tend to target very particular processes. One might accelerate tissue repair. Another might stimulate your body's natural growth hormone production. Another might modulate inflammation in your gut.

Doctors have been prescribing compounded peptides for years - prepared by licensed pharmacies, based on individual prescriptions, for specific patients. This isn't new science. What's new is that 14 of the most popular ones are about to become legally available again after a two-year ban.

What happened in 2023

In 2023, the FDA placed a set of widely used peptides on its "Category 2" list. Category 2 means the FDA has identified concerns significant enough that compounding pharmacies should not prepare the substance while it is under review.

Overnight, licensed pharmacies could no longer compound peptides like BPC-157, Thymosin Alpha-1, TB-500, and a dozen others that doctors had been prescribing for tissue repair, immune support, cognitive function, and longevity.

The stated rationale was safety concerns - immunogenicity (potential immune reactions), manufacturing impurities, and limited large-scale human clinical trial data.

But here's what actually happened: demand didn't disappear. It moved underground. People who had been getting pharmaceutical-grade peptides from licensed pharmacies with sterility testing and certificates of analysis started buying unregulated "research use only" products from gray-market vendors - with no quality controls, no purity verification, no doctor oversight, and no recourse if something went wrong.

What is actually happening in 2026

The body that reviews these substances is the FDA's Pharmacy Compounding Advisory Committee. It met on July 23 and 24, 2026 to consider several peptides for possible inclusion on the 503A Bulks List, the list that determines whether a non-approved substance may be compounded. Based on reporting from the meeting, the committee voted to recommend BPC-157, KPV, TB-500, and MOTS-C, along with Epitalon and Semax, and voted against emideltide. BPC-157 was among those the committee backed.

A committee recommendation is a step in a review, not a decision. The FDA decides separately, through rulemaking, whether to add a substance to the list, and it is not bound by the committee. Coverage of the meeting also noted the recommendations went against concerns raised by the FDA's own staff. So while the vote is real, it does not by itself change what a pharmacy may compound. Treat any claim that BPC-157 is "back" on a specific timeline with caution.

Peptides affected by the Category 2 restrictions

These are peptides that were restricted to Category 2 and that people commonly ask about. Listing them here is not a claim that any of them will return to compounding eligibility. Each has been studied for the research areas noted, and each links to a guide with more detail:

Approximately 5 peptides are expected to stay on Category 2 due to stronger safety concerns or weaker evidence - including Melanotan II (cardiovascular and melanoma risks), GHRP-2 and GHRP-6 (cortisol and prolactin elevation), LL-37 (limited safety data), and PEG-MGF (minimal clinical evidence).

What "Category 1" actually means

This is where most people get confused, so let's be clear:

Category 1 does not mean FDA-approved.

FDA drug approval requires formal Phase I through Phase III clinical trials, standardized dosing, and detailed labeling. None of these peptides have gone through that process. Category 1 simply means a licensed compounding pharmacy can legally prepare the substance under a doctor's prescription.

Think of it this way: your doctor writes a prescription. A licensed, inspected pharmacy makes it specifically for you - in a sterile cleanroom, with pharmaceutical-grade ingredients, under USP 795/797 standards. That's what Category 1 enables. It's not over-the-counter. It's not unregulated. It requires a doctor and a pharmacy.

What you can get right now

Separate from the substances under review, several peptides currently have an established compounding pathway and may be available through licensed pharmacies with a prescription. You can see the current options in our peptide catalog:

• Sermorelin - a growth hormone secretagogue with an established compounding pathway. Studied for sleep quality, body composition, and recovery.
• NAD+ - a coenzyme central to cellular energy production and longevity research. Available as an injectable or IV formulation.
• Glutathione - the body's master antioxidant. Has a USP monograph. Used for detoxification and oxidative stress.
• Low-Dose Naltrexone (LDN) - an FDA-approved substance used off-label at low doses for immune modulation and inflammation.
• Gonadorelin - a GnRH analog used in hormonal health. Added to Category 1 in the September 2024 list update.

Why this matters - even if you're new to peptides

You don't need to be a biohacker to benefit from this. Peptides are studied for things most people deal with:

• Slow recovery from injuries or surgery
• Poor sleep and low energy
• Brain fog and difficulty focusing
• Chronic inflammation and gut issues
• Aging skin and declining vitality
• Stubborn body composition despite diet and exercise

The difference between peptides and most supplements is that peptides are prescribed by a doctor, based on your lab work, and compounded by a licensed pharmacy specifically for you. There's nothing to buy off a shelf and hope it works.

What happens next

The step that would actually change access is a formal FDA update to the 503A Bulks List, published through the Federal Register. Until that happens for a given substance, its status does not change. There is no confirmed date for any such change, and a committee recommendation does not by itself create one.

If a peptide were added in the future:

1. Compounding pharmacies would need time to source pharmaceutical-grade ingredients, validate formulations, and complete stability testing.
2. Access would still require a prescription and a medical evaluation.
3. Appropriateness for any individual is always determined under medical supervision.